U.S. Urea Cycle Disorders Treatment Market, By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)-

Published In : Mar 2023

Code : CMI5594

Pages :155

Formats :

Excel and PDF

Industry : Pharmaceutical

U.S. Urea Cycle Disorders Treatment MarketSize and Trends

U.S. Urea Cycle Disorders Treatment Market Segmentation:

U.S. Urea Cycle Disorders Treatment market is segmented into Treatment Type, Enzyme Deficiency Type, Route of Administration, and Distribution Channel

Based on Treatment Type, the market is segmented into Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others. Due to key players focusing on strategies such as product acquisition to strengthen their product portfolio for the treatment of UCDs, the Glycerol Phenylbutyrate segment accounted for a significant share of 62.8% in the U.S. market in 2023.

In terms of Enzyme Deficiency Type, the U.S. Urea Cycle Disorders Treatment market has been segmented into OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase. Due to increasing incidence of the N-acetylglutamate synthase deficiency in the U.S., N-acetylglutamate Synthase (NAGS) segment is expected to dominate the market over the forecast period.

On the basis of Route of Administration, the market has been divided into Oral and Injectable. Due to the Increasing approvals of oral suspension by regulatory bodies, the Oral segment is expected to dominate the market over the forecast period.

On the basis of Distribution Channel, the market has been divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Due to major players are focusing on running special awareness programs for the treatment of urea cycle disorders through healthcare facilities, the Hospital pharmacies segment expected to dominate the market over the forecast period

Market Trends: Increasing product approvals for Urea Cycle Disorders Treatment by regulatory bodies is expected to boost the growth of the market over the forecast period. Moreover, increasing adoption of inorganic growth strategies by key players for Urea Cycle Disorders Treatment by regulatory bodies is expected to propel the growth of the U.S. Urea Cycle Disorders Treatment market over the forecast period. Manufacturers are focusing on increasing the number of pipeline products for urea cycle disorders and the development of novel treatments for urea cycle disorder, which is expected to propel the market growth of the U.S. urea cycle disorder treatment market over the forecast period. Increasing product approvals for urea cycle disorders.